WO2006070789A1 - 固形状の水中油型エマルジョン - Google Patents
固形状の水中油型エマルジョン Download PDFInfo
- Publication number
- WO2006070789A1 WO2006070789A1 PCT/JP2005/023865 JP2005023865W WO2006070789A1 WO 2006070789 A1 WO2006070789 A1 WO 2006070789A1 JP 2005023865 W JP2005023865 W JP 2005023865W WO 2006070789 A1 WO2006070789 A1 WO 2006070789A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- water
- solid
- electrolyte
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
- A61Q1/06—Lipsticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/0229—Sticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to a solid oil-in-water emulsion. More specifically, the present invention contains an effective concentration of an electrolyte having a physiological function, while the solid state is stably maintained, has a good feeling of use, and the physiological function of the electrolyte is sufficient.
- the present invention relates to a solid composition that can be expressed and also has an oil-in-water type emulsion power. Background art
- water-in-oil emulsions containing liquid oil, solid oil, water and a lipophilic surfactant are generally used (see, for example, Patent Document 1). ).
- an electrolyte particularly a water-soluble or hydrophilic substance that exerts physiological functions when applied to the skin, cannot effectively exhibit its functions. The reason is that in the water-in-oil emulsion, the electrolyte, which is an active ingredient, dissolves and the aqueous phase is surrounded by the oil phase, so that the electrolyte is difficult to contact the skin.
- an oil-in-water emulsion an aqueous phase in which an electrolyte having a physiological function is dissolved is present on the outside, and the permeability of the electrolyte to the skin is enhanced.
- the oil-in-water type emulsion is suitable as a solid preparation of the electrolyte.
- a solid composition having oil-in-water emulsion strength is already known.
- a solid composition having an oil-in-water emulsion strength containing a surfactant, oil, and j8-1,3-glucan is known.
- Patent Document 2 solid cosmetics comprising water, a specific wax ester, an amphoteric surfactant, a specific form of titanium oxide, and an oil-in-water emulsion containing a higher fatty acid
- Patent Document 3 solid cosmetics such as gelatin, polyethylene glycol, oils and water-containing oil-in-water emulsions (see Patent Document 4) have been reported.
- the electrolyte is dissolved in the water phase in the oil-in-water emulsion, gelling of the emulsion is hindered, and solid emulsion cannot be formed or sufficient hardness can be maintained. There is inconvenience that there is not.
- the oil-in-water emulsion may also have the disadvantage that the physiological function of the electrolyte dissolved in the aqueous phase cannot be fully expressed.
- a purine base, a salt thereof, or a water-soluble vitamin is used as an electrolyte.
- a specific amount of purine base or a salt thereof and a specific amount of a water-soluble vitamin are combined. It has been confirmed by the present inventors that there is a tendency to become prominent when used.
- Patent Document 1 JP-A-6-321731
- Patent Document 2 JP-A-8-291021
- Patent Document 3 Japanese Patent Laid-Open No. 9-194331
- Patent Document 4 Japanese Patent Laid-Open No. 2003-95862
- an object of the present invention is to provide a solid composition having an oil-in-water type emulsion power that has sufficient hardness and good usability, and can sufficiently express the physiological function of an electrolyte.
- the present invention has an effective concentration of purine base, a salt thereof, or a water-soluble vitamin, has a good feeling of use while maintaining a stable solid state, and effectively prevents skin pigmentation. It is an object to provide a solid composition having an oil-in-water type emulsion that can be exerted.
- the present invention provides the following solid composition (solid oil-in-water emulsion composition):
- Item 1 (A) Solid oil, (B) Liquid oil, (C) Surfactant, (D) Polyhydric alcohol, (E) Electrolyte, and (F) Oil-in-water emulsion containing water Composition.
- Item 2 The solid composition according to Item 1, wherein (E) the electrolyte is at least one selected from the group power consisting of purine bases, water-soluble vitamins, derivatives of water-soluble vitamins, and salts thereof.
- Item 3. Electrolyte Power Adenosine-3,, 5, -Cyclic phosphate, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate, and salts thereof consisting of at least one selected Item 2.
- E As an electrolyte, it consists of (E-1) at least one selected from the group power consisting of purine bases and salts thereof, and (E-2) water-soluble vitamins, derivatives thereof and salts thereof.
- E-1) at least one selected from the group power consisting of purine bases and salts thereof, and (E-2) water-soluble vitamins, derivatives thereof and salts thereof.
- Item 2. The solid composition according to Item 1, comprising at least one selected from the group.
- the electrolyte is selected from the group consisting of (E-1) adenosine-3,5, -cyclic phosphate, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate, and salts thereof Item 2.
- the solid composition according to Item 1, comprising at least one selected from the group consisting of (E-2) ascorbic acid, a derivative thereof, and a salt thereof.
- E As an electrolyte, (E-1) At least one selected from the group force consisting of adenosine monophosphate and its salt, and (E-2) Ascorbic acid 2-dalcoside and its salt Item 2.
- Item 7. (A) 5 to 50% by weight of solid oil, (B) 10 to 60% by weight of liquid oil, and (C) 1 to 5% of surfactant.
- Item 2 The solid composition according to Item 1, comprising 20% by weight, (D) 5 to 30% by weight of polyhydric alcohol, (E) 0.1 to 20% by weight of electrolyte, and (F) 10 to 50% by weight of water. .
- Item 8 The solid composition according to Item 1, which is a cosmetic.
- Item 9 The solid composition according to Item 1, which is a topical drug.
- Item 10 The solid composition according to Item 1, wherein the form is a lipstick.
- Item 12. (A) solid oil, (B) liquid oil, (C) surfactant, (D) polyhydric alcohol and (F) water, purine base, water-soluble vitamin, water-soluble vitamin derivative, and these Use for the production of a solid oil-in-water emulsion comprising at least one selected from the group consisting of: Item 13. (A) Solid oil, (B) Liquid oil, (C) Surfactant, (D) Polyhydric alcohol and (F) Water, (E-1) Purine base and salts thereof And (E-2) use for the production of a solid oil-in-water emulsion containing at least one selected from the group consisting of water-soluble vitamins, derivatives thereof and salts thereof.
- FIG. 1 is a graph showing the change over time of the melanin index when the lipstick obtained in Example 1 is applied to the lip for 56 days.
- the unit of period (w) on the horizontal axis is week.
- FIG. 2 is a graph showing an index (frequency change, Hz) of lip flexibility after applying the lipstick obtained in Example 1 to the lip for 56 days.
- the solid composition of the present invention comprises (A) solid oil, (B) liquid oil, (C) surfactant, (D) polyhydric alcohol, (E) electrolyte, and (F) water. It is characterized by being an oil-in-water type emulsion.
- solid oil means a solid or semi-solid oil component at room temperature (25 ° C.).
- the (A) solid oil used in the solid composition of the present invention is not particularly limited as long as it is cosmetically or pharmaceutically acceptable, but it is solid at room temperature. desirable.
- solid oils examples include candelilla wax, carnauba wax, hydrogenated jojoba oil, rice bran oil, shellac, lanolin, beeswax, whale wax, and montan wax; ozokerite, ceresin, paraffin, polyethylene wax, microcrystalline wax, Seri And solid esters such as myristyl myristate, cetyl palmitate, cetyl lactate, cholesteryl oleate, phytosteryl oleate, cholesteryl stearate, and cholesteryl hydroxy stearate.
- These solid oils may be used alone or in any combination of two or more.
- a high melting point solid oil having a melting point of 50 ° C. or higher, more preferably 60 ° C.
- a combination of hydrogenated jojoba oil and ceresin, or a combination of hydrogenated jojoba oil and candelilla roll even though it is preferable to use hydrogenated jojoba oil in combination with other waxes, solid hydrocarbons or solid esters. Is the most effective.
- hydrogenated jojoba oil is used in combination with other waxes, solid hydrocarbons or solid esters, for example, with respect to 100 parts by weight of hydrogenated jojoba oil, other waxes, solid hydrocarbons or solid ester strength Usually, it is desirable to combine them at a ratio of 50 to 1000 parts by weight, preferably 100 to 500 parts by weight, more preferably 100 to 300 parts by weight.
- the blending ratio of the (A) solid oil in the solid composition of the present invention is, for example, usually 5 to 50% by weight, preferably (A) the solid oil, based on the total weight of the composition. Is 10 to 40% by weight, more preferably 15 to 30% by weight.
- liquid oil used in the solid composition of the present invention is liquid as long as it is liquid at room temperature (25 ° C) and is cosmetically or pharmaceutically acceptable. It ’s not something.
- liquid oils include liquid hydrocarbons such as squalene, liquid paraffin, liquid isoparaffin, ⁇ -olefinoligomer; isopropyl myristate, otatildodecyl myristate
- Liquid esters such as oleyl oleate, decyl oleate, 2-hexyl decyl isostearate, hexyl decyl dimethyloctanoate, isopropyl palmitate, hexyl laurate, butyl stearate; avocado oil, almond oil, olive oil, sesame oil , Vegetable oils such as sasanca oil, safflower oil, soybean oil, castor oil, camellia oil, corn oil, rapeseed oil, rice bran oil, persic oil, palm kernel oil, palm oil, castor oil, grape seed oil, cottonseed oil; Examples include animal oils such as turtle oil, mink oil, and egg yolk fat oil; silicone oils such as dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, and otamethylcyclotetrasiloxane. These liquid oils are Can be used alone or in
- the liquid oil (B) used in the present invention is preferably a liquid hydrocarbon, a liquid ester and a combination thereof, and more preferably a combination of a liquid hydrocarbon and a liquid ester.
- the mixing ratio is not particularly limited, but as an example, liquid hydrocarbon is contained in 100 parts by weight of liquid ester. The ratio is preferably 30 to 250 parts by weight, more preferably 50 to 150 parts by weight.
- the blending ratio of the (B) liquid oil in the solid composition of the present invention is, for example, generally 10 to 60% by weight of the (B) liquid oil based on the total weight of the composition.
- the range is preferably 15 to 50% by weight, more preferably 15 to 30% by weight.
- the (B) liquid oil is usually 25 to 600 parts by weight, preferably 50 to 400 parts by weight, more preferably 65 parts per 100 parts by weight of the total amount of (A) solid oil. It is desirable that it is contained at a ratio of about 200 parts by weight.
- the (C) surfactant used in the solid composition of the present invention is not particularly limited as long as it is cosmetically or pharmaceutically acceptable, and is a nonionic surfactant, a surfactant. -On-state surfactants, cationic surfactants, and amphoteric surfactants can be used.
- nonionic surfactants used as surfactants include: POE branched alkyl ethers such as POE octyldodecyl ether; POE alkyls such as POE oleyl ether and POE cetyl ether Ether: sorbitan fatty acid esters such as sorbitan monooleate and sorbitan monoisostearate; POE sorbitan fatty acid esters such as monooleic acid POE sorbitan, monoisostearic acid POE sorbitan, monolauric acid POE sorbitan; lipophilic glyceryl monooleate, lipophilic mono Glycerin fatty acid esters such as daricelin stearate and glyceryl myristate; POE glyceryl fatty acid esters such as glyceryl monooleate and POE glycerin; POE alkyl ether ethers such as POE cholesterol
- (C) specific examples of the cationic surfactant used as the surfactant include fatty acid salts such as potassium stearate and triethanolamine stearate, sodium cetyl sulfate and the like.
- POE alkyl ether sulfates such as POE alkyl (12,13) ether sulfate triethanolamine;
- N-acylmethyl taurine salts such as sodium myristoylmethyltaurine; alkyl phosphates such as diethanolamine cetyl phosphate; POE POE alkyl phosphates such as cetyl sodium monoterphosphate; N-acyl amino acids such as N-stearoyl- sodium L-glutamate, N-stearoyl-potassium L-glutamate, N-stearoyl-L-glutamate triethanolamine A salt etc. can be mentioned.
- cationic surfactant used as the surfactant include alkyltrimethylammonium chloride salts such as stearyltrimethylammonium chloride; distearyldimethylammonium chloride. And dialkyldimethylammonium chloride salts such as -um; benzoleconium chloride and the like.
- amphoteric surfactant used as the surfactant (C) include alkyl carboxymethyl hydroxy such as 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolium-mubetaine.
- alkyl carboxymethyl hydroxy such as 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolium-mubetaine.
- examples include ethyl imidazole-betaine; alkylamidopropyl betaines such as amidopropyl laurate; alkyl hydroxysulfobetaines such as lauryl hydroxysulfobetaine.
- these surfactants may be used singly or in any combination of two or more.
- Surfactant is preferably a nonionic surfactant, more preferably lipophilic glyceryl monostearate, POE hydrogenated castor oil, sucrose stearate, and polyglyceryl monostearate.
- the blending ratio of the (C) surfactant in the solid composition of the present invention is usually 1 to 20% by weight of the (C) surfactant, based on the total weight of the composition. Preferably 2-15% by weight, Preferably, a range of 3 to 10% by weight is exemplified.
- the (D) polyhydric alcohol used in the solid composition of the present invention is not particularly limited as long as it is cosmetically or pharmaceutically acceptable.
- Polyhydric alcohol for example, glycerin; polyglycerin such as diglycerin, triglycerin, tetraglycerin; ethylene glycol, diethylene glycol, polyethylene glycol, 1,3-butylene glycol, propylene glycol, dipropylene glycol, isoprene glycol, Alkanediols such as 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol: sugar alcohols such as mannitol, sorbitol, maltitol and fructose.
- the (D) polyhydric alcohol is preferably dalyserin, diglycerin, ethylene glycol, diethylene glycol, polyethylene glycol, 1,3-butylene glycol, dipropylene glycol, isoprene glycol, more preferably glycerin, diglycerin, Dipropylene glycol and 1,3-butylene glycol are listed.
- the blending ratio of the (D) polyhydric alcohol in the solid composition of the present invention is usually 5 to 30% by weight of the (D) polyhydric alcohol, based on the total weight of the composition.
- the range is preferably 10 to 30% by weight, more preferably 15 to 25% by weight.
- the (E) electrolyte used in the present invention is not particularly limited as long as it is cosmetically or pharmaceutically acceptable.
- Specific examples of the electrolyte (E) are those that are applied to the skin and exhibit physiological functions.For example, a wide range of external preparations, particularly those that can be blended in cosmetics, external medicines or quasi-drugs. Can be mentioned.
- Specific examples of the (E) electrolyte include purine bases, pyrimidine bases, water-soluble vitamins, water-soluble vitamin derivatives, amino acids, amino acid derivatives, and salts thereof.
- the purine base is a general term for various derivatives having purines and purine nuclei as a skeleton.
- the purine base include zazanine, guanine, and their deaminated products (hypoxanthine, xanthine), adenosine, guanosine, inosine, adenosine phosphate ester (adenosine 2′-phosphate, adenosine 3′-).
- Phosphate adenosine 5'-phosphate, adenosine 5'-diphosphate, adenosine 5'-triphosphate, adenosine-3 ', 5'-cyclic phosphate (cAMP)), guanos Phosphate esters (guanosine 3'-phosphate, guanosine 5'-phosphate, guanosine 5 and diphosphate, guanosine 5'-triphosphate), ade-oral succinic acid, xanthic acid, inosinic acid, flavin adenine diene Examples include nucleotide (FAD) and nicotinamide adenine dinucleotide (NAD).
- FAD nucleotide
- NAD nicotinamide adenine dinucleotide
- the pyrimidine base is a general term for pyrimidine and various derivatives having a pyrimidine nucleus as a skeleton.
- Examples of the pyrimidine base include uracil, uridine, and uridine phosphate esters (uridine monophosphate (uridine 5'-phosphate, uridine 3'-phosphate, uridine 2'-phosphate), uridine diphosphate, Uridine triphosphates, uridine cyclic phosphates, etc.], deoxyuridine, phosphate esters of deoxyuridine (5'-deoxyuridine diphosphate (dUDP), 5'-deoxyuridyl acid (dUMP), etc.) Cytosine, cytidine, cytidine phosphate (CMP) [cytidine monophosphate (cytidine 5'-phosphate, cytidine 3'-phosphate, cytidine 2'-phosphate), cytidine triphosphate (CTP), Cytidine
- Examples of water-soluble vitamins and derivatives thereof include vitamin B group, ascorbic acid, lipoic acid, and derivatives thereof.
- vitamin B group and its derivatives include vitamin B derivative, vitamin B, vitamin B, vitamin B, vitamin B, piotin, pantothene.
- the vitamin B derivative includes
- Ascorbic acid derivatives include L-ascorbyl phosphate, disodium L-ascorbate sulfate, 2-dalcoside ascorbate, darcosamine ascorbate, L-dehydroascorbic acid, L-ascorbate phosphate. Examples include bill magnesium.
- amino acids and derivatives thereof include serine, glycine, asparagine, aspartic acid, Examples include amino acids such as lysine, arginine, threonine, cysteine, glutamic acid, and pyrrolidone carboxylic acid, and derivatives thereof.
- Examples of the various salts include alkali metal salts such as sodium salts and potassium salts; basic amino acid salts such as arginine and lysine; ammonium salts and triethanolamine salts.
- the electrolyte may be used alone or in combination of two or more.
- electrolytes (E) purine bases, water-soluble vitamins, derivatives of water-soluble vitamins, and salts thereof are suitable in the present invention because they can be applied to the skin and exhibit excellent physiological activity. Used for. Among these, adenosine-3 ', 5'-cyclic phosphate, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate and their salts, when applied to the skin, improve skin metabolism. It is useful because it works to promote skin turnover.
- (E-1) a combination of at least one selected from the group consisting of purine bases and salts thereof and (E-2) a combination of at least one selected from group power consisting of water-soluble vitamins and derivatives thereof; more preferably (E-1) adenosine-3 ', 5, -cyclic phosphate, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate, and at least one selected from the group ( E-2) at least one combination selected from the group consisting of ascorbic acid, its derivatives, and salts thereof;
- (E-1) a group force consisting of adenosine monophosphate and its salt is selected and at least one selected from (E-2) ascorbic acid 2-darcoside and its salt Both are one kind of combination.
- the mixing ratio of the two is, for example, 100 parts by weight of the component (E-1) To (E-2) component in a proportion of 0.5 to 1000 parts by weight, preferably 5 to 500 parts by weight, more preferably 50 to 500 parts by weight Is mentioned. As long as it is within the effective range, it is possible to exhibit the above effect more effectively.
- the proportion of the electrolyte blended in the solid composition of the present invention is not particularly limited as long as the electrolyte exhibits a desired effect according to each (hereinafter referred to as an effective amount). . Specifically, although it varies depending on the type of electrolyte used, it is usually 0.1 to 20% by weight, preferably 1 to 15% by weight, more preferably 3 to 10% by weight, based on the total weight of the composition. The range is exemplified. Although the solid composition of the present invention contains an effective amount of the electrolyte as described above, the usability is good and a stable solid state can be maintained.
- the total amount of the composition (E-1 ) Component is 0.05 to 10% by weight, and the above component (E-2) is 0.05 to 10% by weight; preferably (E-1) component power is 1 to 7% by weight, and (E-2) Component force S0.5 to 10% by weight; more preferably (E-1) Component force S0.5 to 6% by weight, and the above-mentioned (E-2) component is 1 to 10% by weight. Is done.
- the solid composition of the present invention contains (F) water as an essential component.
- the (F) water any of distilled water, ion-exchanged water, sterilized water and the like may be used.
- the proportion of (F) water contained in the solid composition of the present invention is usually 10 to 50% by weight, preferably 10 to 30% by weight, more preferably 10 to 25% by weight, based on the total amount of the composition. Can be mentioned.
- (F) water is, for example, 20 to 60 parts by weight, preferably 20 to 50 parts per 100 parts by weight of the total amount of (A) solid oil and (B) liquid oil. Desirably, it is contained in parts by weight, more preferably 20-40 parts by weight.
- the solid composition of the present invention is not limited to the effects of the present invention, but is limited to ultraviolet absorbers, antioxidants, bactericides, anti-inflammatory agents, antiseptics, and perfumes. Applied to the skin of various known ingredients such as colorants, especially cosmetics and topical pharmaceuticals' quasi drugs The well-known component mix
- the solid composition of the present invention can exhibit physiological functions based on the action of the electrolyte blended in the composition, and is transdermal or transdermal, such as cosmetics or external medicines (including quasi drugs for external use). Used as a mucosal preparation.
- the shape is not particularly limited. It is possible. By making the solid composition of the present invention into a stick-like preparation, it is suitable as a preparation for lips, a partially applied preparation on the skin, particularly a preparation for face.
- the dimensions are not particularly limited, but it is usually molded into a cylindrical shape having a diameter of 7 to 30 mm and a height of about 20 to 50 mm. In order to solidify in a stick shape, it is desirable that the solid composition can be self-supporting.
- being able to stand on its own means that it can hold its own shape without being supported in the side by placing it in a container or the like.
- it can be molded into a cylindrical shape with a diameter of 10 mm and a height of 40 mm.
- the solid composition of the present invention can be prepared by an ordinary method for preparing a solid oil-in-water emulsion.
- the oil phase part was prepared by stirring and dissolving the above components 1 to 8 at 80 ° C, and separately, the water phase part was prepared by stirring and dissolving the above components 9 to 16 at 80 ° C. .
- the oil phase portion was added to the water phase portion to emulsify, poured into a lipstick mold, and cooled to obtain a lipstick composed of an oil-in-water emulsion (a cylinder with a diameter of 10 mm and a height of 40 mm). .
- the above ingredients 1-7 were stirred and dissolved at 80 ° C to prepare an oil phase part. Separately, the above 8-15 ingredients were stirred and dissolved at 80 ° C to prepare an aqueous phase part. . Next, the oil phase portion was added to the water phase portion to emulsify, poured into a lipstick mold, and cooled to obtain a lipstick composed of an oil-in-water emulsion (a cylinder with a diameter of 10 mm and a height of 40 mm). .
- the test sample application site was the entire upper and lower lip.
- the measurement sites were the mucosal region of the lower lip and the mucosal transition site at the skin boundary, and the measurement site of the lower lip was set at the left and right of the midline.
- the evaluation items were the melanin index and flexibility, and the method described below was used.
- the measurement was performed after washing the measurement site with soap (trade name: Kao White, manufactured by Kao Corporation) and acclimatizing the body for 30 minutes in an artificial weather room (temperature 20 ° C, relative humidity 50%).
- the melanin index of the measurement part on the right side of the midline was measured every two weeks.
- This unit irradiates the skin with light of three different wavelengths (568, 660 and 880 nm), and in the case of the melanin index, measures the reflectance of the reflected light from the 660 and 880 nm skin and calculates it as the melanin index. To do.
- the tactile sensor Venustron is a device that contacts a probe that vibrates at a certain frequency with a test substance and measures the softness with the amount of change in the frequency (Af (Hz)). Harder specimens become larger (changes in the positive direction) and softer specimens become smaller (changes in the negative direction).
- the test sample was reciprocated twice over the entire upper and lower lips.
- the number of applications per day should be at least 3 times, and the application time range was after breakfast, after lunch, after dinner, and when the preparation was removed for some reason.
- Application was carried out for 56 consecutive days.
- the application should be at least the normal frequency of use.
- the test subject is restricted (painted) during the test period. (Prohibition of stimulating the cloth with a cloth or towel, prohibition of application of cosmetics, etc. that may affect the test, and prohibition of sunburn).
- Figure 1 shows the changes over time in the melanin index during the test period.
- the melanin index is an index indicating that the larger the value, the greater the amount of melanin.
- the melanin index at the start of the experiment was 81.6, and the melanin index at the end of the experiment was 42.9.
- the melanin index of the lower lip decreased by 38.8. This decrease was also statistically significant (p 0.01).
- Fig. 2 shows the results of evaluating the flexibility of the lips at the start and end of the test.
- the amount of frequency change indicates that the lips are softer as the value is negative.
- the amount of frequency change (lower lip flexibility) was -102.3 Hz at the start of the experiment and -226.0 Hz at the end of the experiment, which was softer at the end of the experiment. This difference was also statistically significant.
- the lipstick before and after storage was evaluated for cracks, color, odor, and feeling of use.
- ⁇ in the table indicates “no abnormality for items before storage”, and “no abnormality and no change compared to before storage” for items after storage.
- (E-1) at least one selected from the group consisting of purine bases and salts thereof and (E-2) water-soluble vitamins and their It is extremely difficult to satisfy all of stable solidification, good usability, and expression of excellent physiological functions by containing an effective amount of at least one selected from the group power of derivatives. It was.
- a solid oil-in-water emulsion that contains all the above-mentioned disadvantages while containing an effective amount of the above-mentioned components (E-1) and (E-2) is prepared. Can be made.
- the solid composition of the present invention is excellent in usability in that it has a good texture and little irritation to the skin. Furthermore, by making the solid composition of the present invention into a stick shape, it is excellent in portability and can be applied locally to the skin of the human body. It is possible to combine both convenience and convenience during use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Colloid Chemistry (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077014814A KR101288110B1 (ko) | 2004-12-28 | 2005-12-27 | 고형의 수중유형 에멀젼 |
EP05822499.9A EP1842522B1 (en) | 2004-12-28 | 2005-12-27 | Solid oil-in-water emulsion |
AU2005320616A AU2005320616B2 (en) | 2004-12-28 | 2005-12-27 | Solid oil-in-water emulsion |
CA 2590928 CA2590928C (en) | 2004-12-28 | 2005-12-27 | Solid oil-in-water emulsion |
ES05822499T ES2736199T3 (es) | 2004-12-28 | 2005-12-27 | Emulsión de aceite en agua sólida |
CN200580045327XA CN101094645B (zh) | 2004-12-28 | 2005-12-27 | 固体水包油型乳剂 |
KR1020137007634A KR20130045406A (ko) | 2004-12-28 | 2005-12-27 | 고형의 수중유형 에멀젼 |
US11/722,965 US8409594B2 (en) | 2004-12-28 | 2005-12-27 | Solid oil-in-water emulsion |
BRPI0519671-0A BRPI0519671A2 (pt) | 2004-12-28 | 2005-12-27 | emulsço sàlida àleo-em-Água |
HK08101428A HK1110516A1 (en) | 2004-12-28 | 2008-02-05 | Solid oil-in-water emulsion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004381162A JP4925579B2 (ja) | 2004-12-28 | 2004-12-28 | 水中油型エマルジョンからなる固形組成物 |
JP2004-381162 | 2004-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006070789A1 true WO2006070789A1 (ja) | 2006-07-06 |
WO2006070789A8 WO2006070789A8 (ja) | 2006-10-05 |
Family
ID=36614902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/023865 WO2006070789A1 (ja) | 2004-12-28 | 2005-12-27 | 固形状の水中油型エマルジョン |
Country Status (12)
Country | Link |
---|---|
US (1) | US8409594B2 (ja) |
EP (1) | EP1842522B1 (ja) |
JP (1) | JP4925579B2 (ja) |
KR (2) | KR20130045406A (ja) |
CN (1) | CN101094645B (ja) |
AU (1) | AU2005320616B2 (ja) |
BR (1) | BRPI0519671A2 (ja) |
CA (1) | CA2590928C (ja) |
ES (1) | ES2736199T3 (ja) |
HK (1) | HK1110516A1 (ja) |
TW (1) | TW200637579A (ja) |
WO (1) | WO2006070789A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016088860A (ja) * | 2014-10-31 | 2016-05-23 | 株式会社コーセー | 化粧料又は皮膚外用剤 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101604778B1 (ko) | 2007-08-06 | 2016-03-18 | 오츠카 세이야쿠 가부시키가이샤 | 아데닌 화합물을 함유하는 겔상 외용 조성물 |
JP5546253B2 (ja) | 2008-01-11 | 2014-07-09 | 大塚製薬株式会社 | 外用組成物 |
ES2959848T3 (es) | 2008-06-09 | 2024-02-28 | Otsuka Pharma Co Ltd | Composición para uso externo |
ES2364443T3 (es) * | 2008-11-19 | 2011-09-02 | Nestec S.A. | El polvo de aceite sólido. |
JP4518520B1 (ja) * | 2009-04-28 | 2010-08-04 | 株式会社資生堂 | 整髪用化粧料 |
JP5483549B2 (ja) * | 2009-12-03 | 2014-05-07 | 花王株式会社 | 固形化粧料 |
DE102011018924A1 (de) | 2011-04-28 | 2012-10-31 | Tunap Industrie Chemie Gmbh & Co. Produktions Kg | OW-Emulsionskonzentrat, Verfahren zu dessen Herstellung und dieses enthaltendes Hautkosmetikum |
FR2996762B1 (fr) * | 2012-10-15 | 2014-11-21 | Oreal | Composition cosmetique de revetement des fibres keratiniques |
FR2996763B1 (fr) * | 2012-10-15 | 2014-11-21 | Oreal | Composition cosmetique de revetement des fibres keratiniques |
FR2996761B1 (fr) * | 2012-10-15 | 2015-01-16 | Oreal | Composition cosmetique de revetement des fibres keratiniques |
KR102564048B1 (ko) * | 2015-09-30 | 2023-08-04 | (주)아모레퍼시픽 | 수중유형 에멀젼 조성물 |
JP6321105B2 (ja) * | 2015-09-30 | 2018-05-09 | 株式会社 資生堂 | 水中油型乳化化粧料 |
BR112018076032B1 (pt) | 2016-07-14 | 2022-04-12 | Unilever Ip Holdings B.V. | Método não terapêutico de reduzir o mau odor na superfície do corpo humano |
KR102371421B1 (ko) * | 2017-06-30 | 2022-03-08 | (주)아모레퍼시픽 | 수중유형 에멀젼 입술용 화장료 조성물 |
WO2019187242A1 (ja) * | 2018-03-28 | 2019-10-03 | 不二製油グループ本社株式会社 | 油脂組成物 |
KR102130298B1 (ko) * | 2018-09-11 | 2020-07-08 | 코스맥스 주식회사 | 유용성 페이스트 또는 겔상의 오일을 포함하는 고형 비드의 제조방법 |
FR3112475B1 (fr) * | 2020-07-20 | 2023-11-10 | Naos Inst Of Life Science | formulation écobiologique, compatible avec la vie cellulaire, utilisable dans les domaines cosmétiques, dermopharmaceutiques ou vétérinaires |
KR102484476B1 (ko) * | 2020-09-14 | 2023-01-04 | 주식회사 한국화장품제조 | 수중유형 유화 스틱형 클레이 마스크 화장료 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08245363A (ja) * | 1995-03-07 | 1996-09-24 | Noevir Co Ltd | 固形状水中油型乳化化粧料 |
JPH09194331A (ja) * | 1996-01-18 | 1997-07-29 | Shiseido Co Ltd | 水中油型の固型乳化化粧料 |
JPH10291914A (ja) * | 1997-04-18 | 1998-11-04 | Noevir Co Ltd | 固形状水中油型乳化化粧料 |
JP2002234830A (ja) * | 2000-11-22 | 2002-08-23 | Otsuka Pharmaceut Co Ltd | O/w型乳化組成物及びその調製方法 |
JP2003113034A (ja) * | 2001-09-28 | 2003-04-18 | Kose Corp | 水中油型化粧料 |
JP2004091399A (ja) * | 2002-08-30 | 2004-03-25 | Hoyu Co Ltd | 整髪剤組成物 |
JP2004238386A (ja) * | 2002-12-11 | 2004-08-26 | Mikimoto Pharmaceut Co Ltd | 医薬品、医薬部外品および化粧品 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5085856A (en) | 1990-07-25 | 1992-02-04 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic water-in-oil emulsion lipstick comprising a phospholipid and glycerol fatty acid esters emulsifying system |
US5763497A (en) * | 1994-07-21 | 1998-06-09 | Shiseido Company, Ltd. | Oil-in-water type cosmetic composition |
JP3555907B2 (ja) | 1995-04-25 | 2004-08-18 | 株式会社ノエビア | 固形状水中油型乳化化粧料 |
JP3578858B2 (ja) * | 1995-12-11 | 2004-10-20 | 株式会社ノエビア | 皮膚外用剤 |
JPH09194330A (ja) * | 1996-01-18 | 1997-07-29 | Shiseido Co Ltd | 水中油型の固型化粧料 |
DE19815086C2 (de) * | 1998-04-06 | 2000-11-30 | Cognis Deutschland Gmbh | Sonnenschutzmittel |
US6455055B1 (en) * | 1999-02-12 | 2002-09-24 | The Procter & Gamble Company | Cosmetic compositions |
FR2807320B1 (fr) * | 2000-04-10 | 2002-05-24 | Oreal | Utilisation de derives d'acide ascorbique pour augmenter la synthese des creramides epidermiques |
JP3565332B2 (ja) | 2000-09-28 | 2004-09-15 | 株式会社ノエビア | 乳化型固形化粧料 |
PT1342462E (pt) * | 2000-11-22 | 2007-06-29 | Otsuka Pharma Co Ltd | Composição de uma emulsão de o/a e processo para a sua preparação. |
JP4955167B2 (ja) | 2001-09-27 | 2012-06-20 | 株式会社コーセー | 水中油型固形化粧料 |
DE10154368A1 (de) * | 2001-11-06 | 2003-05-15 | Henkel Kgaa | Beta-Glucuronidase-Inhibitoren in Deodorantien und Antitranspirantien |
JP4129574B2 (ja) * | 2002-08-06 | 2008-08-06 | 大塚製薬株式会社 | 老化防止剤 |
-
2004
- 2004-12-28 JP JP2004381162A patent/JP4925579B2/ja active Active
-
2005
- 2005-12-27 EP EP05822499.9A patent/EP1842522B1/en not_active Not-in-force
- 2005-12-27 CN CN200580045327XA patent/CN101094645B/zh not_active Expired - Fee Related
- 2005-12-27 WO PCT/JP2005/023865 patent/WO2006070789A1/ja active Application Filing
- 2005-12-27 ES ES05822499T patent/ES2736199T3/es active Active
- 2005-12-27 US US11/722,965 patent/US8409594B2/en active Active
- 2005-12-27 BR BRPI0519671-0A patent/BRPI0519671A2/pt not_active IP Right Cessation
- 2005-12-27 KR KR1020137007634A patent/KR20130045406A/ko not_active Application Discontinuation
- 2005-12-27 CA CA 2590928 patent/CA2590928C/en not_active Expired - Fee Related
- 2005-12-27 AU AU2005320616A patent/AU2005320616B2/en not_active Ceased
- 2005-12-27 KR KR1020077014814A patent/KR101288110B1/ko active IP Right Grant
- 2005-12-28 TW TW094147002A patent/TW200637579A/zh not_active IP Right Cessation
-
2008
- 2008-02-05 HK HK08101428A patent/HK1110516A1/xx not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08245363A (ja) * | 1995-03-07 | 1996-09-24 | Noevir Co Ltd | 固形状水中油型乳化化粧料 |
JPH09194331A (ja) * | 1996-01-18 | 1997-07-29 | Shiseido Co Ltd | 水中油型の固型乳化化粧料 |
JPH10291914A (ja) * | 1997-04-18 | 1998-11-04 | Noevir Co Ltd | 固形状水中油型乳化化粧料 |
JP2002234830A (ja) * | 2000-11-22 | 2002-08-23 | Otsuka Pharmaceut Co Ltd | O/w型乳化組成物及びその調製方法 |
JP2003113034A (ja) * | 2001-09-28 | 2003-04-18 | Kose Corp | 水中油型化粧料 |
JP2004091399A (ja) * | 2002-08-30 | 2004-03-25 | Hoyu Co Ltd | 整髪剤組成物 |
JP2004238386A (ja) * | 2002-12-11 | 2004-08-26 | Mikimoto Pharmaceut Co Ltd | 医薬品、医薬部外品および化粧品 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016088860A (ja) * | 2014-10-31 | 2016-05-23 | 株式会社コーセー | 化粧料又は皮膚外用剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2006182746A (ja) | 2006-07-13 |
TWI373346B (ja) | 2012-10-01 |
JP4925579B2 (ja) | 2012-04-25 |
EP1842522B1 (en) | 2019-05-15 |
EP1842522A4 (en) | 2015-07-08 |
CA2590928C (en) | 2013-06-25 |
US8409594B2 (en) | 2013-04-02 |
AU2005320616B2 (en) | 2011-07-14 |
AU2005320616A1 (en) | 2006-07-06 |
EP1842522A1 (en) | 2007-10-10 |
US20070280979A1 (en) | 2007-12-06 |
CA2590928A1 (en) | 2006-07-06 |
BRPI0519671A2 (pt) | 2009-03-03 |
CN101094645B (zh) | 2013-04-03 |
CN101094645A (zh) | 2007-12-26 |
KR20070095305A (ko) | 2007-09-28 |
HK1110516A1 (en) | 2008-07-18 |
KR101288110B1 (ko) | 2013-07-19 |
WO2006070789A8 (ja) | 2006-10-05 |
KR20130045406A (ko) | 2013-05-03 |
TW200637579A (en) | 2006-11-01 |
ES2736199T3 (es) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006070789A1 (ja) | 固形状の水中油型エマルジョン | |
JP4129574B2 (ja) | 老化防止剤 | |
WO2004004676A1 (ja) | ベシクル分散物およびこれを含有する化粧料 | |
JP4425127B2 (ja) | 肝斑改善用組成物及びくすみ改善用組成物 | |
TWI324932B (en) | Sugar-uptake promoting agent | |
AU2009203355B2 (en) | Composition for external application | |
KR101028478B1 (ko) | 경피흡수 촉진용 유성 피부외용 조성물 | |
CA2508093A1 (en) | Preparation for external use on skin | |
JP2006225271A (ja) | シワの予防又は改善剤 | |
JP6046882B2 (ja) | 皮膚用水中油型乳化組成物 | |
JP2000198718A5 (ja) | ||
US20060030621A1 (en) | Preparation for external use on skin | |
JP2000198718A (ja) | 血行促進外用剤 | |
JP4741109B2 (ja) | 油性化粧料 | |
EP1093800B1 (en) | Cosmetic composition | |
Pawar Champat et al. | A SHORT REVIEW ON NOVEL APPROCH OF CREAM. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2005320616 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007501174 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2590928 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4618/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11722965 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2005320616 Country of ref document: AU Date of ref document: 20051227 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580045327.X Country of ref document: CN Ref document number: 1020077014814 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005320616 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005822499 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005822499 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11722965 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0519671 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020137007634 Country of ref document: KR |